Autopsy report · NCT06592664

Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

“Management Decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Lisata Therapeutics, Inc.

Sponsor type

Industry

Conditions

Pancreas Cancer; Pancreatic Carcinoma; Pancreas Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer

Interventions

certepetide; nab-paclitaxel; gemcitabine; placebo matching certepetide; certepetide; placebo matching certepetide

Participants

0

Trials that died the same way

• HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
  “Business decision” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.